{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=115", "query": { "condition": "Advanced Malignancy", "page": 115 }, "page_size": 10 }, "pagination": { "page": 115, "page_size": 10, "total_count": 9821, "total_pages": 983, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=116&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=114&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-13T18:55:15.456Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04959266", "title": "A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumours" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Rifampicin", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 5, "start_date": "2021-06-28", "completion_date": "2022-06-01", "has_results": false, "last_update_posted_date": "2022-09-16", "last_synced_at": "2026-11-13T18:55:15.456Z", "location_count": 3, "location_summary": "Portland, Oregon • Austin, Texas • Dallas, Texas", "locations": [ { "city": "Portland", "state": "Oregon" }, { "city": "Austin", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04959266" }, { "nct_id": "NCT01562015", "title": "A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Ganetespib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Synta Pharmaceuticals Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2012-04", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2015-05-20", "last_synced_at": "2026-11-13T18:55:15.456Z", "location_count": 2, "location_summary": "Tampa, Florida • Cleveland, Ohio", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01562015" }, { "nct_id": "NCT05836324", "title": "A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Advanced Solid Tumors", "Metastatic Solid Tumors" ], "interventions": [ { "name": "INCA33890", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "ADG126", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 570, "start_date": "2023-07-24", "completion_date": "2029-05-03", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-11-13T18:55:15.456Z", "location_count": 11, "location_summary": "Los Angeles, California • Boston, Massachusetts • Grand Rapids, Michigan + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05836324" }, { "nct_id": "NCT02981303", "title": "Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Melanoma", "Triple-Negative Breast Cancer" ], "interventions": [ { "name": "Imprime PGG", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "HiberCell, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2017-02-22", "completion_date": "2020-12-31", "has_results": true, "last_update_posted_date": "2024-07-09", "last_synced_at": "2026-11-13T18:55:15.456Z", "location_count": 10, "location_summary": "Avondale, Arizona • Santa Monica, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Avondale", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Athens", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02981303" }, { "nct_id": "NCT00804154", "title": "Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Intractable Pain", "Palliative Care" ], "interventions": [ { "name": "Intrathecal Resiniferatoxin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Dental and Craniofacial Research (NIDCR)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 36, "start_date": "2009-08-14", "completion_date": "2026-07-14", "has_results": false, "last_update_posted_date": "2026-10-30", "last_synced_at": "2026-11-13T18:55:15.456Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00804154" }, { "nct_id": "NCT06090266", "title": "A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Tumor, Solid", "Malignant Neoplasm", "Metastatic Cancer", "Advanced Solid Tumor", "Cutaneous Melanoma", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "OR502", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoResponse, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2023-10-24", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2025-01-07", "last_synced_at": "2026-11-13T18:55:15.456Z", "location_count": 4, "location_summary": "Austin, Texas • Irving, Texas • San Antonio, Texas + 1 more", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Irving", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06090266" }, { "nct_id": "NCT04630756", "title": "AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Haematological Malignancies" ], "interventions": [ { "name": "AZD4573", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 40, "start_date": "2021-02-17", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2025-04-09", "last_synced_at": "2026-11-13T18:55:15.456Z", "location_count": 4, "location_summary": "Duarte, California • La Jolla, California • Houston, Texas + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04630756" }, { "nct_id": "NCT00100256", "title": "Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Carcinoma, Small Cell", "Neoplasm Recurrence, Local" ], "interventions": [ { "name": "Rhenium (Re 188 P2045, BAY86-5284)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Andarix Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 60, "start_date": "2004-01", "completion_date": "2025-04-20", "has_results": false, "last_update_posted_date": "2022-11-07", "last_synced_at": "2026-11-13T18:55:15.456Z", "location_count": 2, "location_summary": "Iowa City, Iowa • Baltimore, Maryland", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00100256" }, { "nct_id": "NCT06030622", "title": "Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer Metastatic" ], "interventions": [ { "name": "Gemcitabine and C3 (Metformin, Simvastatin, and Digoxin)", "type": "DRUG" }, { "name": "C3 (Metformin, Simvastatin, and Digoxin) only", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "State University of New York - Downstate Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2024-04-17", "completion_date": "2028-12-30", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-11-13T18:55:15.456Z", "location_count": 1, "location_summary": "Brooklyn, New York", "locations": [ { "city": "Brooklyn", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06030622" }, { "nct_id": "NCT01407562", "title": "Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor - Protocol Specific", "Breast Cancer - Female" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2010-09-17", "completion_date": "2016-03-29", "has_results": false, "last_update_posted_date": "2022-09-28", "last_synced_at": "2026-11-13T18:55:15.456Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01407562" } ] }